MRG003

MRG003 is an antibody-drug conjugate developed by Lepu Biopharma. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05751512 (A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN), in head and neck squamous cell carcinoma and nasopharyngeal carcinoma. The largest, NCT05126719, plans to enrol 238 participants with primary completion expected 2024-12-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.